MRI-LINAC Radiation for Prostate Cancer with Dr. Michael J. Zelefsky

The Dr. Geo Prostate Podcast

What if prostate cancer treatment weren’t months of daily radiation—but five ultra-precise sessions guided in real time by MRI? Today, Dr. Michael J. Zelefsky (Professor of Radiation Oncology, NYU Grossman School of Medicine) explains how MRI-LINAC and adaptive planning are redefining accuracy, reducing side effects, and personalizing care. A pioneer behind IMRT and image-guided radiotherapy, Dr. Zelefsky breaks down SBRT vs. IMRT, protons vs. photons, HDR brachytherapy, when to add hormone therapy, and how genomics + AI are shaping what’s next.

In this conversation, Dr. Zelefsky charts the evolution from long-course radiation to short-course SBRT with outcomes comparable to 7–9 week regimens—thanks to precision imaging and planning. He clarifies where IMRT ends and SBRT begins, why protons haven’t shown superiority over photons in prostate cancer, and where HDR brachytherapy (Ir-192) shines—especially as a boost in higher-risk disease. We dig into dose equivalence (why 5×8 Gy can match ~80–90 Gy long-course), risk-based treatment + ADT duration, and how Decipher/Artera scores can refine decisions. Most exciting: MRI-LINAC with continuous motion monitoring keeps the prostate in a virtual “bullseye,” enabling whole-gland treatment with focal boosts today—and potentially true focal therapy tomorrow as biologic imaging and AI mature.

Time-Stamped Highlights

00:00 – Welcome

02:00 – Why Dr. Zelefsky’s work is so respected; career arc and impact

04:00 – What changed: CT/MRI planning → 3D-CRT → IMRT → SBRT

12:45 – IMRT vs. SBRT: definitions, session counts, who gets what

19:10 – Energy sources overview: photons, protons, brachytherapy

20:30 – Protons vs. photons: evidence, indications, cost, access

24:00 – HDR brachytherapy (Ir-192) as a temporary “in-and-out” boost

28:00 – Dose logic: why 5×8 Gy (~40 Gy) ≈ long-course 80–90 Gy

29:30 – Risk groups (low/intermediate/high) and when ADT is crucial

33:00 – ADT durations (6–36 months): what trials actually showed

37:00 – Genomics (Decipher/Artera): resolving risk discrepancies

39:00 – What MRI-LINAC adds: real-time adaptive planning

43:00 – Continuous Motion Monitoring (CMM): beam stops if target moves

47:00 – Treat whole gland + boost the DIL (FLAME study approach)

49:00 – Toward focal therapy with better biologic imaging + AI

54:00 – How to choose: values, side-effects, lifestyle, comorbidities

01:01:00 – Final guidance: don’t be overwhelmed—multiple good option

🌱 Partner Offers

ProLon 5-Day Fasting Mimicking Diet — Enjoy fasting benefits with food. Supports cellular renewal, metabolic health, and fat loss. Special offer for our listeners: Get the ProLon kit for $148 → https://bit.ly/3TVehAx

AG1 by Athletic Greens — 75 high-quality vitamins, minerals, probiotics, and adaptogens in one daily scoop. Supports gut health, immunity, energy, and focus. Try it here → https://bit.ly/3mA2tVV

💪 Exclusive Membership

Want deeper insights? Join The Dr. Geo Prostate Podcast Exclusive Membership for curated transcripts, detailed show notes, expert resources, and member perks. → https://drgeo.com/membership

📌 Follow and Connect

📺 YouTube → Dr. Geo Prostate Podcast / @drgeoprostatepodcast

🎧 Listen to All Episodes → https://dr-geo-prostate-podcast.capti...

🛒 Shop Dr. Geo’s supplements → XY Wellness https://bit.ly/3uJPC7Z

| Mr. Happy https://bit.ly/3TE7tWE

📸 Instagram → https://bit.ly/DRGEO-INSTA-YT

📘 Facebook → https://bit.ly/POD-FB-DrGeo

💼 LinkedIn → https://bit.ly/DRGEO-LINKEDIN-YT

🌐 Website → https://bit.ly/43khht0

📣 Hashtags

#DrGeoProstatePodcast #ProstateHealth #ProstateCancer #MensHealth #IntegrativeUrology #RadiationOncology #SBRT #MRILINAC

⚠️ Disclaimer

This podcast is for educational purposes only and not medical advice. The views expressed are Dr. Geo’s and not those of his employer(s) or affiliated organizations. Use of this content is at your own risk. Geovanni Espinosa, N.D., assumes no liability for direct or indirect consequences, including economic loss, injury, illness, or death.